Zydus Pharmaceuticals, Mexico

Zydus Pharmaceuticals (Mexico) Service Co.S.A. de C.V. is located in Cartera Picacho Ajusco no 154, Ofna 601-B Col. Jardines en la Montania, Tlaplpan, C.p. 14210 Mexico, and is the Mexico. division of Cadila Healthcare. Since our first commercial launch was in June 2013, Zydus is focused on providing outstanding customer service, along with high-quality, affordable generic products to our customers and their patients. Zydus Mexico looks to redefine the standards for pharmaceutical performance, shaped by a passion to deliver value through innovation and an unwavering commitment to compliance. At Zydus Mexico, business success is equated with an environment in which employees are encouraged to maximize their potential through personal growth and accountability. USA HOME??? :????

Zydus is a vertically integrated generic pharmaceutical company.?We manufacture over 50% of our product?s active pharmaceutical ingredient (API) and in fact take it a few steps further by even manufacturing our own bottles in US.? Recently, the group launched Exemptia, the world?s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only Indian pharma company to launch its own patented NCE ? Lipaglyn, the world?s first drug to be approved for the treatment of diabetic dyslipidemia. Cadilla cuenta con 36 registros autorizados por la Secretaria de Salud, de los cuales se comercializan 15. En el plan de lanzamiento de nuevos productos hasta el momento se cuenta con 5 productos nuevos.

Zydus Cadila, a leading Indian Pharmaceutical company is a fully integrated, global healthcare provider. With in-depth domain expertise in the field of healthcare, it has strong capabilities across the spectrum of the pharmaceutical value chain. From formulations to active pharmaceutical ingredients and animal healthcare products to wellness products, Zydus has earned a reputation amongst Indian pharmaceutical companies for providing comprehensive and complete healthcare solutions.

One of the salient features of Zydus is its rich history and lineage. The origin of the company dates all the way back to the 1950s. The company was founded in the year 1952 by Mr. Ramanbhai B. Patel (late), a first-generation entrepreneur and a doyen in the field of Indian Pharmaceuticals.

In 1995, the group was restructured and thus was formed Cadila Healthcare under the aegis of the Zydus group. From a humble turnover Rs. 250 crores in 1995 the group witnessed a significant financial growth and registered a turnover of over Rs. 12,700 crores in FY19.

Adhering to its brand promise of being dedicated to life in all its dimensions, Zydus continues to innovate with an unswerving focus to address the unmet healthcare needs. Simultaneously it rededicates itself to its mission of creating healthier, happier communities across the globe.

A vision that unleashes value

Zydus shall be a leading global healthcare provider with a robust product pipeline; Opening up new pathways through innovation and quality excellence, we shall be a research-driven pharmaceutical company by 2020.

Mission Statement

A mission to create healthier communities

Zydus Cadila is dedicated to life? In all its dimensions. Our world is shaped by a passion for innovation, commitment to partners and concern for people in an effort to create healthier communities, globally.

Global

Globally, Zydus has a strong presence in the regulated markets of the US, Europe (France & Spain) and the high profile markets of Latin America and South Africa. It also has a strong presence in 25 other emerging markets worldwide. It aims to be a leading global healthcare provider with a robust product pipeline; achieve sales of over Rs. 10000 crore by 2015 and be a research-based pharmaceutical company by 2020.It also has a strong presence in 25 other emerging markets worldwide.

Parent Company

Zydus Cadila is a fully integrated, global healthcare provider, with strengths all along the pharmaceutical value chain. With a core competence in the field of healthcare, Zydus Cadila provides total healthcare solutions ranging from formulations, active pharmaceutical ingredients and animal healthcare products to wellness products.

Recently, the group launched Exemptia, the world?s first biosimilar for Adalimumab, the largest selling therapy worldwide for inflammatory arthritis. Zydus is also the only Indian pharma company to launch its own patented NCE ? Lipaglyn, the world?s first drug to be approved for the treatment of diabetic dyslipidemia.

The group?s origin can be traced to 1952 when it was founded by Late Mr. Ramanbhai B. Patel, a first-generation entrepreneur and one of the stalwarts of the Indian Pharmaceutical Industry. In 1995, the group restructured its operations and Cadila Healthcare came into being under the aegis of the Zydus group. Zydus Cadila, today, is spearheaded by Mr. Pankaj R. Patel, the Chairman and Managing Director of the group.

As one of the key players amongst the pharmaceutical manufacturing companies, the group has manufacturing capabilities across the entire pharmaceutical value chain: including formulations, APIs, vaccines, biosimilars, complex products (transdermals, topical etc.), animal health products and wellness products. It has more than 30 manufacturing plants worldwide including India, Brazil and USA.

Key Attributes

• 4th largest player in the Indian pharma market. (AWACS May 2015)

• 15 of the group?s brands feature amongst the top 300 pharma brands in India. (AWACS May 2015)

• World class manufacturing facilities comprising state-of-the-art manufacturing plants for APIs and formulations, including novel dosage forms. Of these, 5 are USFDA inspected.

• Robust regulatory pipeline ? 260 ANDAs have been filed of which 99 have been approved. The group has filed 116 DMFs.

• The first Indian pharma company to launch an NCE in the market with Lipaglyn, the world?s first drug to treat diabetic dyslipidemia.

• Launched the world?s first biosimilar of Adalimumab ?Exemptia? to treat inflammatory arthritis.

• Robust innovation pipeline with over 1200 researchers working across 5 R&D centers of excellence focused on small molecules, biologics, vaccines, formulation development and API process research.

• Partner of Choice for research-driven pharma majors like Abbott, Hospira, Bayer, Takeda, IDRI, Pieris AG, Prolong Pharmaceuticals and the World Health Organization to name a few.

For more information, please visit?www.zyduscadila.com.

Contact Us
Zydus Mexico Corporate Office:

Zydus Pharmaceuticals Mexico Service Co. S.A. de C.V.
Cartera Picacho Ajusco no 154, Ofna 601-B Col

Jardines en la Montania, Tlaplpan, C.p. 14210

Mexico Phone:?3089-3587 / 5630-5463
Fax:?609-730-1998

Other Locations:

Cadila Healthcare Ltd:
Zydus Tower
Satellite Cross Roades
Ahmedabad 380015 India